289 related articles for article (PubMed ID: 36995469)
21. Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis.
Jadon DR; Sengupta R; Nightingale A; Lindsay M; Korendowych E; Robinson G; Jobling A; Shaddick G; Bi J; Winchester R; Giles JT; McHugh NJ
Ann Rheum Dis; 2017 Apr; 76(4):701-707. PubMed ID: 27913376
[TBL] [Abstract][Full Text] [Related]
22. Responsiveness of Serum C-Reactive Protein, Interleukin-17A, and Interleukin-17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double-Blind, Placebo-Controlled Trials.
Siebert S; Sweet K; Dasgupta B; Campbell K; McInnes IB; Loza MJ
Arthritis Rheumatol; 2019 Oct; 71(10):1660-1669. PubMed ID: 31070869
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study.
Mease PJ; Gladman DD; Poddubnyy D; Chakravarty SD; Shawi M; Kollmeier AP; Xu XL; Xu S; Deodhar A; Baraliakos X
Rheumatol Ther; 2023 Dec; 10(6):1637-1653. PubMed ID: 37819505
[TBL] [Abstract][Full Text] [Related]
24. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.
Deodhar A; Blauvelt A; Lebwohl M; Feely M; Kronbergs A; Eberhart N; Zhu D; Inman E; Grace E; Holzkaemper T; Rahman P; Marzo-Ortega H; Papp KA; Merola JF; Gottlieb AB; Schwartzman S
Arthritis Res Ther; 2024 Feb; 26(1):49. PubMed ID: 38347650
[TBL] [Abstract][Full Text] [Related]
25. IL-23 inhibition for the treatment of psoriatic arthritis.
Mohanakrishnan R; Beier S; Deodhar A
Expert Opin Biol Ther; 2022 Jan; 22(1):59-65. PubMed ID: 34092169
[TBL] [Abstract][Full Text] [Related]
26. Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials.
Helliwell PS; Gladman DD; Chakravarty SD; Kafka S; Karyekar CS; You Y; Campbell K; Sweet K; Kavanaugh A; Gensler LS
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32209721
[TBL] [Abstract][Full Text] [Related]
27. Dactylitis Is Associated With More Severe Axial Joint Damage and Higher Disease Activity in Axial Psoriatic Arthritis.
Li SS; Du N; He SH; Liang X; Li TF
J Rheumatol; 2022 Sep; 49(9):1012-1019. PubMed ID: 35501145
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the Possibility of Axial Psoriatic Arthritis Patients Meeting Classification Criteria for Axial Spondyloarthritis and Ankylosing Spondylitis.
Gubar EE; Korotaeva TV; Korsakova YL; Loginova EY; Smirnov AV; Sukhinina AV; Urumova MM; Glukhova SI
Dokl Biochem Biophys; 2024 Jun; ():. PubMed ID: 38861144
[TBL] [Abstract][Full Text] [Related]
29. Treatment Patterns and Healthcare Resource Utilization Among Newly Diagnosed Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, and Hidradenitis Suppurativa Patients with Past Diagnosis of an Inflammatory Condition: A Retrospective Cohort Analysis of Claims Data in the United States.
Hopson S; Gibbs LR; Syed S; Low R; McClung L; Beaty S
Adv Ther; 2023 Oct; 40(10):4358-4376. PubMed ID: 37486558
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for axial inflammatory arthritis in patients with psoriatic arthritis.
Chandran V; Tolusso DC; Cook RJ; Gladman DD
J Rheumatol; 2010 Apr; 37(4):809-15. PubMed ID: 20231209
[TBL] [Abstract][Full Text] [Related]
32. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries.
Egeberg A; Rosenø NAL; Aagaard D; Lørup EH; Nielsen ML; Nymand L; Kristensen LE; Thyssen JP; Thomsen SF; Cordtz RL; Loft N; Skov L; Bryld LE; Rasmussen MK; Højgaard P; Kristensen S; Dreyer L
Semin Arthritis Rheum; 2022 Apr; 53():151979. PubMed ID: 35183936
[TBL] [Abstract][Full Text] [Related]
33. Enthesitis in patients with psoriatic arthritis and axial spondyloarthritis - data from the Danish nationwide DANBIO registry.
Mathew AJ; Glintborg B; Krogh NS; Hetland ML; Østergaard M
Semin Arthritis Rheum; 2022 Feb; 52():151948. PubMed ID: 35027245
[TBL] [Abstract][Full Text] [Related]
34. Type I and III collagen turnover is increased in axial spondyloarthritis and psoriatic arthritis. Associations with disease activity and diagnostic capacity.
Gudmann NS; Siebuhr AS; Christensen AF; Ejstrup L; Sørensen GL; Loft AG; Karsdal MA; Bay-Jensen AC; Munk HL; Junker P
Clin Exp Rheumatol; 2017; 35(4):653-659. PubMed ID: 28240584
[TBL] [Abstract][Full Text] [Related]
35. Targeted Therapies in Axial Psoriatic Arthritis.
Floris A; Congia M; Chessa E; Angioni MM; Piga M; Cauli A
Front Genet; 2021; 12():689984. PubMed ID: 34262600
[TBL] [Abstract][Full Text] [Related]
36. Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies.
Sánchez-Rodríguez G; Puig L
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373452
[TBL] [Abstract][Full Text] [Related]
37. Management of Axial Spondyloarthritis - Insights into Upadacitinib.
Braun J; Kiltz U; Baraliakos X
Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520
[TBL] [Abstract][Full Text] [Related]
38. Heterogeneity of axial spondyloarthritis: genetics, sex and structural damage matter.
Li Z; van der Linden SM; Khan MA; Baumberger H; Zandwijk HV; Khan MK; Villiger PM; Brown MA
RMD Open; 2022 May; 8(1):. PubMed ID: 35523521
[TBL] [Abstract][Full Text] [Related]
39. Higher frequency but similar recurrence rate of uveitis episodes in axial spondylarthritis compared to psoriatic arthritis. A multicentre retrospective study.
Kougkas N; Magiouf K; Gialouri CG; Evangelatos G; Pappa M; Dimouli A; Iliopoulos A; Karmanakos A; Dimitroulas T; Tektonidou MG; Sfikakis PP; Fragoulis GE
Rheumatol Int; 2023 Nov; 43(11):2081-2088. PubMed ID: 37610650
[TBL] [Abstract][Full Text] [Related]
40. IL-23 in axial spondyloarthritis and psoriatic arthritis: a good fit for biological treatment?
Atzeni F; Siragusano C; Masala IF; Antonio C; Valentina P; D'Angelo S
Expert Opin Biol Ther; 2022 Jul; 22(7):843-853. PubMed ID: 35722768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
